Berubicin

NEW APPROACH TO GLIOBLASTOMA TREATMENT ADDRESSING THE CRITICAL UNMET MEDICAL NEED.

OVERVIEW

Berubicin is an exciting new drug that is one of the first anthracyclines proven to cross the blood brain barrier (BBB) and able to reach brain tumors. This discovery can potentially extend the clinical use of anthracyclines to brain tumors, specifically GBM.

CLINICAL DEVELOPMENT

Berubicin’sPhase I clinical trial, the first time it was tested in humans, yielded very promising results with 44% of the patients showing a clinical response. In addition, Berubicin has shown evidence of improved overall survival in a patient population that currently has a dismal median survival rate of only 14.6 months from diagnosis.

Berubicin

GRANTS / FUNDING

  • In February 2019, WPD was awarded a $6 million-dollar grant from the National Centre for Research and Developmentin Poland for the continued development of Berubicin in adult and in pediatric population
  • Previous grants and direct investments have totaled more than $25 million focused on developing Berubicin

REGULATORY

Berubicin has previously received an Orphan Drug designation in the US, which provides seven years of marketing exclusivity.

PARTNERS, AFFILIATIONS & LICENSE

  • ReataPharmaceutical (Nasdaq: RETA) - $3 Billion- dollar Nasdaq listed company
  • Houston Pharmaceuticals
  • MD Anderson, leading cancer research center in the world
  • CNS Pharmaceutical – co-development partner
  • WPD owns the exclusive license to 30 countries in Europe and Asia and also Russia

This project is co-financed by the European Union from the European Regional Development Fund under the Smart Growth Operational Program 2014-2020, Sectoral Programme InnoNeuroPharm, Priority Axis I: Support R&D carried out by enterprises,Measure 1.2: Sectoral R&D Programmes, implemented under National Center for Research and Development.

Co-financing of the project from the EU: 22 033 066,00 PLN

R & D